Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Vaxcyte (PCVX) Gains from Sales and Divestitures (2022 - 2023)

Vaxcyte (PCVX) has 2 years of Gains from Sales and Divestitures data on record, last reported at $232890.0 in Q4 2023.

On a quarterly basis, Gains from Sales and Divestitures rose 193.95% to $232890.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $232890.0, a 193.95% increase, with the full-year FY2023 number at $232890.0, up 193.95% from a year prior.
Gains from Sales and Divestitures reached $232890.0 in Q4 2023 per PCVX's latest filing, up from $216636.0 in the prior quarter.
Over the last five years, Gains from Sales and Divestitures for PCVX hit a ceiling of $232890.0 in Q4 2023 and a floor of $45206.0 in Q1 2023.